Beginning in April 2023, there have been reports of Syfovre eye injury cases, including retinal vasculitis resulting in significant vision loss. As of the beginning of April 2024, however, retina specialists seem to agree that both the etiology and the incidence rate of retinal vasculitis after Syfovre injections remain uncertain. Put in more … [Read more...]
Syfovre Eye Injuries Decreased Vision For Patients After Syfovre Treatments
Members of the American Society of Retina Specialists (ASRS) Research and Safety in Therapeutics (ReST) Committee recently issued a general report on cases where Syfovre eye injuries decreased vision for patients after Syfovre treatments. In summary, this report revealed that at least 13 patients had Syfovre retinal-related vision loss in … [Read more...]
Wegovy / Rybelsus / Ozempic DVT Blood Clots Side Effects Cases
Wegovy, Rybelsus, and Ozempic DVT blood clots side effects have not received as much attention as adverse event reports that involve severe stomach conditions such as gastroparesis, gastric stasis, and stomach paralysis. Ozempic, Wegovy, and Rybelsus are three popular GLP-1 receptor agonists containing semaglutide that are increasingly used as … [Read more...]
Gastroparesis Cases Involving Ozempic, Rybelsus, Wegovy, and Trulicity as Weight-loss Drugs
We are handling gastroparesis cases involving Ozempic, Rybelsus, Wegovy, and Trulicity as drug injury lawsuits filed against the responsible pharmaceutical companies. In this piece, we point out two medical journal articles that present a few gastroparesis cases involving the use of semaglutide (Ozempic, Rybelsus, Wegovy) or dulaglutide … [Read more...]
Prolia Drug Label Change: Warning for Severe Hypocalcemia in Patients With Chronic Kidney Disease
A January 2024 Prolia drug label change that added a “Black-Box” warning for the “new” Prolia hypocalcemia side effect was announced through this Drug Safety Communication “FDA adds Boxed Warning for increased risk of severe hypocalcemia in patients with advanced chronic kidney disease taking osteoporosis medicine Prolia (denosumab).” This … [Read more...]
Syfovre Safety Issues Raised In December 2023 JAMA Viewpoint Piece
A December 2023 JAMA Ophthalmology Viewpoint piece about Syfovre safety issues was reported on in a December 7, 2023, Managed Healthcare Executive article, “Independent Assessment of Syfovre Needed, Argues JAMA Ophthalmologist Viewpoint”: An independent panel of retinal specialists and statisticians should assess the clinical trial data for … [Read more...]
New Syfovre Warnings for Retinal Vascular Occlusion and Retinal Vasculitis
A November 2023 label change added new Syfovre warnings for retinal vascular occlusion and retinal vasculitis cases associated with Syfovre injections. With these new Syfovre warnings, it now seems that the retinal vascular occlusion and retinal vasculitis cases associated with Syfovre use are due to the drug itself and not the injection kits, as … [Read more...]
Syfovre Vision Side Effects Cases Reported at Ophthalmology Meeting
A Syfovre vision side effects cases presentation was one of the most important at the 2023 Annual Meeting of the American Academy of Ophthalmology (AAO) in San Francisco in early November. William J. Johnson, M.D., of the Wolfe Clinic in Iowa, reported on Syfovre vision side effects cases ranging from hemorrhagic occlusive vasculitis-type … [Read more...]
Wegovy, Rybelsus, and Ozempic Linked to Gastroparesis by Medical Study
Patients who use drugs containing semaglutide are at an increased risk of gastroparesis, according to an October 2023 medical journal article about patients who used two different types of weight-loss drugs. The Novo Nordisk drugs Wegovy, Rybelsus, and Ozempic each have semaglutide as their active ingredient. Accordingly, Wegovy, Rybelsus, and … [Read more...]
Retinal Vasculitis Cases Caused by Syfovre Injection Kits With a 19-gauge Filter Needle?
In what seems to be the latest Syfovre safety update, in early October 2023 Apellis reported an increase in the number of Syfovre retinal vasculitis cases, but Apellis did not provide any significant new information regarding an “explanation” as to how certain Syfovre injection kits might have caused these adverse reaction events. EndPoints News … [Read more...]
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 8
- Next Page »